Bristol-Myers Squibb will collaborate with Adaptive Biotechnologies to develop immunological biomarkers for cancer, representing another step forward in the development of personalized medicine.
Researchers in Australia have identified 9 blood-based biomarkers that correspond with PET imaging measurements of amyloid beta protein, a brain plaque that can signify the advance of Alzheimer's disease.
Scanning the field of biomarker research for cardiovascular disease, a group of investigators has found some compelling data that suggest the effect of thebiomarkers is regularly exaggerated, with signs of bias in the reports. And that clearly could be hurting the medical field's understanding of the biomarkers' significance.
The investigators identified 59 available meta-analyses for review with 49 claiming statistically significant results, according to a report in Cardiology Today. But the largest studies with the most subjects had the smallest effects, with a host of smaller studies claiming the most dramatic results. And that indicates bias in the selection of which reports were published, tilting the field toward the positive and away from the negative. Read the full story >>
A blood test to determine a patient's suicide risk may be within reach. Scientists at the University of New South Wales in Australia and colleagues in Sweden believe they've come up with a viable diagnostic biomarker: higher-than-normal levels of the neurotransmitter quinolinic acid. Through their work with an unnamed biotech, they expect to debut a working blood test for human clinical trials within the next year, the Australian Times reports. Ideally, such a test would process results with a day or two, enabling targeted personalized medicine-style treatments specific to reducing levels of quinolinic acid. Read more >>
POPULAR COMMENT THREADS
The hormone adrenomedullin is secreted by the fetus during pregnancy and appears to keep pregnant women from developing preeclampsia. And they believe it could become an effective biomarker to help pinpoint patients more likely to develop the dangerous condition.
Researchers at the Montreal Heart Institute have ferreted out a blood protein that could help diagnose atherosclerosis, a thickening of the arterial wall that can lead to heart attack.
Another team of researchers is tackling the task of developing a blood test designed to predict a patient's likelihood of suffering a heart attack. And they've zeroed on three promising biomarkers to help get the job done.
New genetic and epigenetic alterations in the genome discovered by scientists at The Cancer Genome Atlas Research Network offer promising disease markers for acute myeloid leukemia--a finding that may have narrowed the search for drug targets.
A group of investigators say they put one theory related to prostate cancer to the test, and came up with some data indicating it's a dead end for developers as well as doctors looking for the right therapeutic strategy for patients.
A massive, international study to find and evaluate potential Parkinson's disease biomarkers has finished enrolling a first group of 600 Parkinson's patients and controls.
From Our Sister Sites
Natick, MA-based Karyopharm Therapeutics has banked $48.2 million in Series B cash. The funds will be used to advance its pipeline of selective inhibitors of nuclear export (SINE) drug candidates for hematologic and solid tumors.
The agency has given the coveted status to the Lexington, MA-based biotech company's experimental treatment for use against early onset lysosomal acid lipase deficiency, an inherited disorder that typically kills infants within the first 6 month of life, according to the company.